Funding Opportunity RFA-NS-22-031 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA), issued by NINDS, is to invite currently awarded NeuroNEXT sites and potential new sites to participate as a Clinical Site in the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). This clinical research network develops and conducts multiple, scientifically sound, possibly biomarker-informed exploratory clinical trials evaluating the most promising therapies for neurological disorders, whether from academic, foundation or industry discoveries. Examples include Phase 2 clinical trials and clinical research studies aimed at validating biomarkers and clinical outcomes in preparation for clinical trials. The network provides a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in neurological disorders affecting adult and/or pediatric populations. While the network is not specific to one disease, it has the capacity to coordinate a cadre of specialist investigators to implement studies efficiently in response to disease-specific opportunities. This FOA solicits applications for Clinical Sites. Separate FOAs solicit applications for the Clinical Coordinating Center and the Data Coordinating Center.

Funding Opportunity RFA-DA-23-039 from the NIH Guide for Grants and Contracts. This FOA solicits the development of theories, computational models, and analytical tools to derive understanding of brain function from complex neuroscience data. Proposed projects could develop tools to integrate existing theories or formulate new theories; conceptual frameworks to organize or fuse data to infer general principles of brain function; multiscale/multiphysics models to generate new testable hypotheses to design/drive future experiments; new analytical methods to either support or refute a stated hypothesis about brain function. It is expected that the tools developed under this FOA will be made widely available to the neuroscience research community for their use and modification. Investigative studies should be limited to model parameter estimation and/or validity testing of the tools being developed.

Develop robust analytical pipelines for analysis of a wide range of next generation sequencing data. Support the Data Science team in developing new methods for…
From Cellular Dynamics - Tue, 20 Sep 2022 05:25:19 GMT - View all Madison, WI jobs

Funding Opportunity RFA-MH-22-271 from the NIH Guide for Grants and Contracts. Although the majority living with schizophrenia and related disorders are over 35 years old, including those first diagnosed and those aging with the illness, the mechanisms underlying the generation and trajectory of the illness remain poorly understood. The purpose of this initiative is to advance translational research to better understand the emergence and trajectory of schizophrenia and related disorders in mid to late life, and to identity targets for future development of prevention and treatment efforts

Funding Opportunity RFA-MH-22-270 from the NIH Guide for Grants and Contracts. Although the majority living with schizophrenia and related disorders are over 35 years old, including those first diagnosed and those aging with the illness, the mechanisms underlying the generation and trajectory of the illness remain poorly understood. The purpose of this initiative is to advance translational research to better understand the emergence and trajectory of schizophrenia and related disorders in mid to late life, and to identity targets for future development of prevention and treatment efforts

Funding Opportunity RFA-TR-22-032 from the NIH Guide for Grants and Contracts. This FOA provides support using the SBIR cooperative agreement mechanisms for the development, regulatory qualification and commercialization of alternative approaches methods (NAMs) that specifically utilizes the neuromuscular junction Tissue Chips (TC) platforms that will replace the LD50 assay (mouse lethality bioassay (MLB) as a potency assay for botulinum toxin. The NIH NCATS and FDA are partners in this FOA and will collaborate and coordinate efforts with award recipients. The goal of this collaboration is to establish the Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCh) as a Drug Development Tool (DDT). A main objective for this funding opportunity would be to position BoT PATCh as an alternative test method that can be utilized as a stand-alone replacement for MLB. As a cooperative agreement, small business concerns (SBCs) will be expected to work with NIH and FDA staff to develop and implement the final validation plan for the proposed alternative test method.

Funding Opportunity RFA-TR-22-031 from the NIH Guide for Grants and Contracts. This FOA provides support using the STTR cooperative agreement mechanisms for the development, regulatory qualification and commercialization of alternative approaches methods (NAMs) that specifically utilizes the neuromuscular junction Tissue Chips (TC) platforms that will replace the LD50 assay (mouse lethality bioassay (MLB) as a potency assay for botulinum toxin. The NIH NCATS and FDA are partners in this FOA and will collaborate and coordinate efforts with award recipients. The goal of this collaboration is to establish the Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCh) as a Drug Development Tool (DDT). A main objective for this funding opportunity would be to position BoT PATCh as an alternative test method that can be utilized as a stand-alone replacement for MLB. As a cooperative agreement, small business concerns (SBCs) will be expected to work with NIH and FDA staff to develop and implement the final validation plan for the proposed alternative test method.

Notice NOT-RM-23-004 from the NIH Guide for Grants and Contracts

Notice NOT-HL-22-047 from the NIH Guide for Grants and Contracts

Notice NOT-HL-22-044 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-126 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-23-035 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) aims to support complementary research programs that adopt innovative scalable technologies to inventory, register and profile cellular ensembles and/or cell-types that produce and/or respond to opioids in the brain, or that are engaged during different stages of opioid use (acute, chronic, withdrawal, abstinence, relapse). Emphasis is on approaches capable of integrating data generated through molecular profiling of brain tissues at single-cell resolution with other data modalities , such as neurophysiological activity, connectivity and/or spatial localization, collected from the same cells. The overarching goal of the FOA is to generate and disseminate multimodal reference datasets that will be useful to the research community and will provide a foundational biological framework to advance the understanding of opioid-associated states.

Notice NOT-CA-22-128 from the NIH Guide for Grants and Contracts

Notice NOT-HD-22-043 from the NIH Guide for Grants and Contracts

Perform and develop routine and complex computational and database methods for implementation. Collaborate with principal investigator and bioinformatics team…
From Medical College of Wisconsin - Mon, 19 Sep 2022 03:14:53 GMT - View all Milwaukee, WI jobs

Experience: 2 years work-related experience in molecular assays, nucleic acid sequencing and basic bioinformatic analysis. $45,936 - $67,479 a year
From University of Wyoming - Sat, 17 Sep 2022 02:14:32 GMT - View all Laramie, WY jobs

Notice NOT-OD-22-211 from the NIH Guide for Grants and Contracts

Conduct metagenomic analysis and sequencing analysis. Experience in microbial ecology, molecular methods and/or bioinformatics to characterized mixed microbial…
From Marquette University - Fri, 16 Sep 2022 16:22:11 GMT - View all Milwaukee, WI jobs

Funding Opportunity RFA-HG-22-021 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the development, implementation, and maintenance of the AnVIL Clinical Resource (ACR), a suite of genomic-based clinical tools and services built into the NHGRI Data Science Analysis, Visualization, and Informatics Lab-Space (AnVIL) to foster clinical genomic research. AnVIL is a scalable and interoperable resource for the basic and clinical genomic research communities that leverages a cloud-based infrastructure to democratize data access, sharing, and computing across large genomic and genomic-related datasets.

Funding Opportunity RFA-NR-23-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages UG3/UH3 phased cooperative research applications to accelerate implementation of effective non-opioid interventions for chronic pain management in rural and remote populations. Projects include pragmatic, implementation, or hybrid effectiveness-implementation trials to improve pain management and reduce the use of inappropriate opioid medications. Awards made under this FOA will initially support a milestone-driven, planning phase (UG3) of 1 to 2 years, with possible transition to an implementation phase (UH3) of up to 4 years duration (5 years total for the two phases). UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The overall goal of this initiative is to support the "real world" implementation of effective interventions to manage pain in rural and remote areas. Results from the trials supported by this funding opportunity announcement (FOA) should inform policy makers, payers, community stakeholders, as well as health care providers and patients in the primary care, emergency department, hospital, home health, or dental setting. This FOA requires that the investigators partner with one or more rural healthcare system(s) to plan and implement the intervention. During the planning phase, investigators must develop an additional one or more community-based partnership(s). Studies may propose to integrate multi-component, bundled, or multi-level interventions that have demonstrated efficacy.